Answers are grounded in this paper and cite their sources.
Background: Natural bioactives derived from medicinal plants and dietary sources have long been used to manage metabolic and hepatic disorders. However, their application in metabolic dysfunction-associated steatotic liver disease (MASLD) is restricted by poor solubility, instability, low bioavailability, rapid metabolism, and insufficient hepatic exposure. This review evaluates the pharmacological mechanisms and therapeutic potential of nanostructured natural bioactives for MASLD. Methods: Published preclinical and clinical evidence on natural bioactives and their nanostructured formulations for MASLD was narratively reviewed. Evidence was synthesized according to nanocarrier type, pharmacokinetic advantages, mechanisms of action, therapeutic outcomes, safety, and clinical translation. Results: The included studies primarily covered three categories: nanostructured natural small-molecule bioactives, bioactive fractions, and single-source therapeutics. Small-molecule bioactives constituted the largest group, encompassing flavonoids, polyphenols, terpenoids, alkaloids, and lignans. Liposomes, nanoemulsions, polymeric nanoparticles, and micelles were the principal delivery platforms used to improve effective exposure through encapsulation, protection, and controlled release. Mechanisms included modulation of AMPK, SREBP-1c/FAS-, and PPARα/CPT-1-related lipid metabolism, suppression of NF-κB-associated inflammation, and enhancement of Nrf2-related antioxidant defenses, collectively attenuating hepatic lipid accumulation and injury. Nanostructured bioactive fractions and single-source therapeutics additionally involved multicomponent interactions, intestinal barrier protection, and gut–liver axis modulation. Nanostructured small-molecule bioactives showed translational promise, with oral nano-curcumin providing preliminary clinical evidence, although its additional benefits on hepatic fat content were inconsistent. Naturally derived vesicle-like nanoparticles also showed potential, but their compositional standardization, in vivo behavior, and long-term safety require further investigation. Conclusions: Nanostructuring may improve the pharmacokinetic performance and pharmacological efficacy of natural bioactives against MASLD. Future studies should prioritize standardized formulation characterization, dose–exposure–response relationships, direct comparisons with free bioactives, long-term safety, and clinical trials.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: